EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells

Role of c-Jun N-terminal kinase

Tetsuya Yamamoto, Hari Digumarthi, Zina Aranbayeva, John Wataha, Jill Lewis, Regina L W Messer, Haiyan Qin, Douglas Dickinson, Tokio Osaki, George S. Schuster, Stephen Hsu

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The green tea polyphenol epigallocatechin-3-gallate (EGCG) regulates gene expression differentially in tumor and normal cells. In normal human primary epidermal keratinocytes (NHEK), one of the key mediators of EGCG action is p57/KIP2, a cyclin-dependent kinase (CDK) inhibitor. EGCG potently induces p57 in NHEK, but not in epithelial cancer cells. In humans, reduced expression of p57 often is associated with advanced tumors, and tumor cells with inactivated p57 undergo apoptosis when exposed to EGCG. The mechanism of p57 induction by EGCG is not well understood. Here, we show that in NHEK, EGCG-induces p57 via the p38 mitogen-activated protein kinase (MAPK) signaling pathway. In p57-negative tumor cells, JNK signaling mediates EGCG-induced apoptosis, and exogenous expression of p57 suppresses EGCG-induced apoptosis via inhibition of c-Jun N-terminal kinase (JNK). We also found that restoration of p57 expression in tumor cells significantly reduced tumorigenicity in athymic mice. These results suggest that p57 expression may be an useful indicator for the clinical course of cancers, and could be potentially useful as a target for cancer therapies.

Original languageEnglish (US)
Pages (from-to)318-325
Number of pages8
JournalToxicology and Applied Pharmacology
Volume224
Issue number3
DOIs
StatePublished - Nov 1 2007

Fingerprint

JNK Mitogen-Activated Protein Kinases
Cells
Carcinoma
Tumors
Neoplasms
Keratinocytes
Apoptosis
Cyclin-Dependent Kinases
epigallocatechin gallate
Polyphenols
p38 Mitogen-Activated Protein Kinases
Tea
Gene expression
Nude Mice
Restoration
Phosphotransferases
Epithelial Cells
Gene Expression

Keywords

  • EGCG
  • JNK
  • MAPK
  • Oral carcinoma
  • p57/KlP2

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells : Role of c-Jun N-terminal kinase. / Yamamoto, Tetsuya; Digumarthi, Hari; Aranbayeva, Zina; Wataha, John; Lewis, Jill; Messer, Regina L W; Qin, Haiyan; Dickinson, Douglas; Osaki, Tokio; Schuster, George S.; Hsu, Stephen.

In: Toxicology and Applied Pharmacology, Vol. 224, No. 3, 01.11.2007, p. 318-325.

Research output: Contribution to journalReview article

Yamamoto, T, Digumarthi, H, Aranbayeva, Z, Wataha, J, Lewis, J, Messer, RLW, Qin, H, Dickinson, D, Osaki, T, Schuster, GS & Hsu, S 2007, 'EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells: Role of c-Jun N-terminal kinase', Toxicology and Applied Pharmacology, vol. 224, no. 3, pp. 318-325. https://doi.org/10.1016/j.taap.2006.11.013
Yamamoto, Tetsuya ; Digumarthi, Hari ; Aranbayeva, Zina ; Wataha, John ; Lewis, Jill ; Messer, Regina L W ; Qin, Haiyan ; Dickinson, Douglas ; Osaki, Tokio ; Schuster, George S. ; Hsu, Stephen. / EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells : Role of c-Jun N-terminal kinase. In: Toxicology and Applied Pharmacology. 2007 ; Vol. 224, No. 3. pp. 318-325.
@article{be5f54b48bc342c28dff5287bd78628f,
title = "EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells: Role of c-Jun N-terminal kinase",
abstract = "The green tea polyphenol epigallocatechin-3-gallate (EGCG) regulates gene expression differentially in tumor and normal cells. In normal human primary epidermal keratinocytes (NHEK), one of the key mediators of EGCG action is p57/KIP2, a cyclin-dependent kinase (CDK) inhibitor. EGCG potently induces p57 in NHEK, but not in epithelial cancer cells. In humans, reduced expression of p57 often is associated with advanced tumors, and tumor cells with inactivated p57 undergo apoptosis when exposed to EGCG. The mechanism of p57 induction by EGCG is not well understood. Here, we show that in NHEK, EGCG-induces p57 via the p38 mitogen-activated protein kinase (MAPK) signaling pathway. In p57-negative tumor cells, JNK signaling mediates EGCG-induced apoptosis, and exogenous expression of p57 suppresses EGCG-induced apoptosis via inhibition of c-Jun N-terminal kinase (JNK). We also found that restoration of p57 expression in tumor cells significantly reduced tumorigenicity in athymic mice. These results suggest that p57 expression may be an useful indicator for the clinical course of cancers, and could be potentially useful as a target for cancer therapies.",
keywords = "EGCG, JNK, MAPK, Oral carcinoma, p57/KlP2",
author = "Tetsuya Yamamoto and Hari Digumarthi and Zina Aranbayeva and John Wataha and Jill Lewis and Messer, {Regina L W} and Haiyan Qin and Douglas Dickinson and Tokio Osaki and Schuster, {George S.} and Stephen Hsu",
year = "2007",
month = "11",
day = "1",
doi = "10.1016/j.taap.2006.11.013",
language = "English (US)",
volume = "224",
pages = "318--325",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells

T2 - Role of c-Jun N-terminal kinase

AU - Yamamoto, Tetsuya

AU - Digumarthi, Hari

AU - Aranbayeva, Zina

AU - Wataha, John

AU - Lewis, Jill

AU - Messer, Regina L W

AU - Qin, Haiyan

AU - Dickinson, Douglas

AU - Osaki, Tokio

AU - Schuster, George S.

AU - Hsu, Stephen

PY - 2007/11/1

Y1 - 2007/11/1

N2 - The green tea polyphenol epigallocatechin-3-gallate (EGCG) regulates gene expression differentially in tumor and normal cells. In normal human primary epidermal keratinocytes (NHEK), one of the key mediators of EGCG action is p57/KIP2, a cyclin-dependent kinase (CDK) inhibitor. EGCG potently induces p57 in NHEK, but not in epithelial cancer cells. In humans, reduced expression of p57 often is associated with advanced tumors, and tumor cells with inactivated p57 undergo apoptosis when exposed to EGCG. The mechanism of p57 induction by EGCG is not well understood. Here, we show that in NHEK, EGCG-induces p57 via the p38 mitogen-activated protein kinase (MAPK) signaling pathway. In p57-negative tumor cells, JNK signaling mediates EGCG-induced apoptosis, and exogenous expression of p57 suppresses EGCG-induced apoptosis via inhibition of c-Jun N-terminal kinase (JNK). We also found that restoration of p57 expression in tumor cells significantly reduced tumorigenicity in athymic mice. These results suggest that p57 expression may be an useful indicator for the clinical course of cancers, and could be potentially useful as a target for cancer therapies.

AB - The green tea polyphenol epigallocatechin-3-gallate (EGCG) regulates gene expression differentially in tumor and normal cells. In normal human primary epidermal keratinocytes (NHEK), one of the key mediators of EGCG action is p57/KIP2, a cyclin-dependent kinase (CDK) inhibitor. EGCG potently induces p57 in NHEK, but not in epithelial cancer cells. In humans, reduced expression of p57 often is associated with advanced tumors, and tumor cells with inactivated p57 undergo apoptosis when exposed to EGCG. The mechanism of p57 induction by EGCG is not well understood. Here, we show that in NHEK, EGCG-induces p57 via the p38 mitogen-activated protein kinase (MAPK) signaling pathway. In p57-negative tumor cells, JNK signaling mediates EGCG-induced apoptosis, and exogenous expression of p57 suppresses EGCG-induced apoptosis via inhibition of c-Jun N-terminal kinase (JNK). We also found that restoration of p57 expression in tumor cells significantly reduced tumorigenicity in athymic mice. These results suggest that p57 expression may be an useful indicator for the clinical course of cancers, and could be potentially useful as a target for cancer therapies.

KW - EGCG

KW - JNK

KW - MAPK

KW - Oral carcinoma

KW - p57/KlP2

UR - http://www.scopus.com/inward/record.url?scp=35348916537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348916537&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2006.11.013

DO - 10.1016/j.taap.2006.11.013

M3 - Review article

VL - 224

SP - 318

EP - 325

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 3

ER -